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Background:  Resistin  is a peptide  hormone  that  is  secreted  from  lipid  cells  and  is linked  to type-2  diabetes,
obesity,  and inﬂammation.  Being  an  important  adipocytokine,  resistin  was proven  to play  an important
role  in cardiovascular  disease.  We  compared  resistin  levels  in  patients  with  and  without  atrial  ﬁbrillation
(AF)  to demonstrate  the  relationship  between  plasma  resistin  levels  and  AF.
Method: One hundred  patients  with  AF  and  58 control  patients  who  were  matched  in  terms  of age,
gender,  and risk  factors  were  included  in  the  trial.  Their  clinical  risk  factors,  biometric  measurements,
echocardiographic  work  up,  biochemical  parameters  including  resistin  and  high-sensitivity  C-reactive
protein  (hs-CRP)  levels  were  compared.
Results:  In  patients  with  AF, plasma  resistin  levels  (7.34  ±  1.63  ng/mL  vs 6.67  ±  1.14  ng/mL;  p =  0.003)  and
hs-CRP  levels  (3.01 ± 1.54  mg/L  vs  2.16  ± 1.28  mg/L;  p =  0.001)  were  higher  than  control  group.  In sub-
group  analysis,  resistin  levels  were  signiﬁcantly  higher  in  patients  with  paroxysmal  (7.59  ± 1.57 ng/mL;
p  =  0.032)  and  persistent  AF (7.73  ±  1.60  ng/mL;  p =  0.006),  but  not  in patients  with  permanent  AF  sub-
groups  (6.86  ± 1.61  ng/mL;  p =  0.92)  compared  to controls.  However,  hs-CRP  levels  were  signiﬁcantly
higher  only  in  permanent  AF patients  compared  to  control  group  (3.26  ± 1.46  mg/L  vs 2.16  ± 1.28 mg/L;
p  =  0.02).  In multivariate  regression  analysis  using  model  adjusted  for age,  gender,  body  mas  index,
hypertension,  diabetes  mellitus,  and creatinine  levels,  plasma  resistin  levels  [odds  ratio  (OR):  1.30;  95%
conﬁdence  interval  (CI):  1.01–1.70;  p = 0.04] and  hs-CRP  levels  (OR:  1.44;  95%  CI:  1.12–1.86; p  =  0.004)
were  the  only  independent  predictors  of  AF.
Conclusion:  The  elevated  levels  of plasma  resistin  were  related  to  paroxysmal  AF  group  and  persistent  AF
group, but  not  to  permanent  AF group.
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Atrial ﬁbrillation (AF) is the most commonly seen and treated
rrhythmia in clinical practice [1]. In previous studies age, diabetes,
ypertension, and cardiovascular diseases were proven to increase
he risk of AF development [2]. Besides these, obesity directly or
ndirectly increases the risk of AF development [3]. Inﬂammation
lays a leading role in the electrical and structural remodeling pro-
ess in AF patients [4,5]. In a prospective study the basal C-reactive
rotein (CRP) levels were strongly and independently correlated
ith future AF development [6]. In addition, higher CRP levels wereinked with the clinical severity of AF [7–9]. Interleukin (IL)-6 and
umor necrosis factor (TNF)- were also found to be signiﬁcantly
igh in AF patients [10]. These studies regarding inﬂammation
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show its potential role in development, progression, and morbidity
of the disease.
Resistin is a hormone that is abundantly secreted from the lipid
cells and linked to type 2 diabetes and obesity. Obese people have
a higher resistin level as compared to healthy ones and this cor-
relates with body mass index (BMI) [11]. Studies done on patients
who have inﬂammation proved that a correlation existed between
resistin and inﬂammation markers [12].
Being an important adipocytokinine secreted from lipid cells,
resistin was  proven to play an important role in cardiovascular
disease. There are many trials conducted on various forms of coro-
nary artery diseases. Reilly et al. proved that resistin levels were
increased in parallel to other inﬂammatory markers and indepen-
dently increased levels were correlated with increased coronary
calcium scores determined by coronary computed tomography (CT)
angiography [13]. Its importance as a marker of adverse cardio-
vascular event development was  proven in studies conducted on
patients with stable coronary artery disease [14–16]. In acute coro-
nary syndrome patients, its prognostic effects on cardiovascular
vier Ltd. All rights reserved.
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vents and mortality were shown [17–20]. Resistin also plays a role
n pathogenesis of heart failure and is associated with the prognosis
21–25].
Obesity and related diseases are important risk factors for
F [26]. As shown in clinical trials, resistin and adiponectin
re related to certain AF risk factors such as inﬂamma-
ion, diabetes, obesity, myocardial infarction, and heart failure
20–23,27–30].
As resistin levels are increased in inﬂammation, diabetes,
besity, coronary artery disease, and heart failure, it raised
 question of whether resistin and other pro-inﬂammatory
dipocytokines secreted from the adipose tissue played a role
n pathogenesis of AF. Adipocytokines may  contribute to AF
ither directly or indirectly through risk factors or inﬂammation
31].
Based on the aforementioned data, in our study we  compared
lasma resistin levels of the patients listed below and its role in
athogenesis:
. Those with and without AF
. In three subgroups of AF which were paroxysmal, persistent, and
permanent.
aterials and methods
atient population
Our research was conducted between January 2011 and July
012 in our tertiary reference center, Siyami Ersek Training
nd Research Hospital. We  prospectively included 100 patients
ith AF who were admitted to our outpatient clinics. Patients
igned informed consent forms upon entering. All patients’
lectrocardiogram (ECG) recordings were recorded and their pre-
ious ECG recordings were evaluated. All patients’ age, gender,
eight, weight, waist circumference, current diseases, cardio-
ascular disease histories, family histories (regarding AF and
AD) were obtained and they were all evaluated for hyper-
ension and diabetes. BMI  was calculated using the formula
eight (kg)/height (m)2. A detailed physical examination was  per-
ormed.
AF was classiﬁed as paroxysmal when episodes were self-
erminating and lasted no longer than 7 days. Persistent AF was
eﬁned as AF episodes lasting longer than 7 days or requiring termi-
ation by cardioversion. Patients with AF of ≥6 months in duration
nd ≥1 attempt of unsuccessful cardioversion to restore normal
inus rhythm were considered to have permanent AF. The patients
ere followed up for one year. Recurrence of AF was  deﬁned as
eadmission with symptoms of palpitation and an episode of AF
as documented by ECG.
All of the study participants underwent two-dimensional and
oppler echocardiography by an experienced echocardiography
pecialist using a Vivid 3 (GE Healthcare Systems, Piscataway,
J, USA) device. The systolic and diastolic diameters of the left
entricle, left atrial size, and volumes were measured. Left ventri-
ular ejection fraction was calculated using the modiﬁed Simpson’s
ethod.
Patients with systolic heart failure (left ventricular ejection
raction <45%), heart failure with preserved ejection fraction,
ypertrophic cardiomyopathy, dilated cardiomyopathy, restric-
ive cardiomyopathy, congenital heart disease, acute coronary
yndrome, valvular heart disease, post-operative AF, chronic
iver/kidney disease, inﬂammatory or autoimmune diseases, malig-
ity, infection, unstable angina, and acute coronary syndrome were
xcluded from the trial.iology 63 (2014) 308–312 309
Biochemical analysis
A peripheral blood sample was  collected into a 5 mL  dry tube
from all those who  entered the research. They were centrifuged for
10 min  at 1000 × g to get the serum. One of each patient’s serum
samples was  kept at −20 ◦C until the biochemical analysis could
detect resistin levels. Routine hemogram parameters [hemoglobin,
hemotocrit, thrombocyte count, mean platelet volume (MPV), red
blood cell dispersion width (RDW), blood glucose, urea, creatinine,
sodium, potassium, CRP, aspartate aminotransferase, and alanine
aminotransferase] were worked up.
Serum resistin levels were measured with the sandwich enzyme
linked immunosorbent assay (ELISA) method which includes the
binding of resistin in the samples to antibodies in solid microplate
wells followed by the addition of anti-human resistin antibodies
conjugated with biotin. The result was  multiplied by 20, which is
the dilution coefﬁcient. Human resistin ELISA kit (Adipo-bioscience,
Santa Clara, CA, USA) was  used for the measurement. The normal
range was 4–16 ng/mL.
Fifty-eight individuals who  were matched in age, gender, and
conventional risk factors and had normal ﬁndings in physical
and echocardiographic examination were recruited as the control
group. The study was approved by the institutional ethics commit-
tee.
Statistical analysis
All data are presented as mean ± SD or median (interquartile
range) for parametric variables and as percentages for categori-
cal variables. Continuous variables were checked for the normal
distribution assumption using the Kolmogorov–Smirnov statistics.
Differences between AF subgroups and control subjects were eval-
uated using the Kolmogorov–Smirnov test or ANOVA with the
Tukey’s post hoc test as appropriate. Categorical variables were
tested by Pearson’s 2 test and Fisher’s exact test. The correlations
between single variables were evaluated with Pearson or Spearman
correlation tests. Forward stepwise multivariate logistic regres-
sion models were created to identify the independent predictors
of AF. Variables with a p-value <0.10 in univariate analysis were
included in the multivariate model. A p-value <0.05 was consid-
ered statistically signiﬁcant. All statistical studies were carried out
using Statistical Package for Social Sciences software (SPSS 16.0 for
Windows, SPSS Inc., Chicago, IL, USA).
Results
The study population consisted of 100 patients with AF (parox-
ysmal AF 28 cases; persistent AF 32 cases; permanent AF 40 cases)
(mean age 60.7 ± 11.7 years) and 58 controls (mean age 57.7 ± 11.1
years). The clinical and laboratory parameters were compared
within the AF subgroups and between the AF and the control group
and are reported in Table 1. Control subjects were matched to AF
patients on the basis of age, gender, body mass index, measured
blood pressure, and prevalence of hypertension, diabetes mellitus,
and smoking. Patients with permanent AF were older, had higher
rates of hypertension, and had reduced left ventricular ejection
fraction compared to paroxysmal and persistent AF subgroups. BMI
and systolic/diastolic blood pressure measurements were similar
between the AF subgroups. The rate of beta blocker use was signif-
icantly higher in patients with AF compared to the control group
(p = 0.01), but was  similar within the AF subgroups (p = 0.65). The
rate of recurrence was  3.4 ± 1.4 episodes/year in paroxysmal AF and
3.2 ± 1.2 episodes/year in persistent AF patients.
Resistin and hs-CRP levels were signiﬁcantly higher in AF
patients compared to the control group (7.34 ± 1.63 ng/mL
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Table 1
Clinical and demographic properties of control group and patients with atrial ﬁbrillation.
Atrial ﬁbrillation group (n = 100) Control group (n = 58) p* p**
Paroxysmal AF (n = 28) Persistent AF (n = 32) Permanent AF (n = 40)
Age (years) 56.6 ± 14.8 60.1 ± 10.7 64.1 ± 9.1 57.7 ± 11.1 0.04 0.11
Male  gender (%) 13(46.4) 13(40.6) 12(30) 28(48.3) 0.36 0.20
Body  mass index (kg/m2) 28.5 ± 3.8 28.9 ± 4.3 27.1 ± 5.2 28.3 ± 4.1 0.22 0.71
Hypertension (%) 13(46.4) 22(68.7) 34(85) 35(60.4) 0.01 0.27
Diabetes mellitus (%) 8(28.6) 7(21.8) 10(25) 15(25.9) 0.84 0.90
Hyperlipidemia (%) 8(28.6) 8(25) 9(22.5) 20(34.5) 0.85 0.20
Current smoker (%) 5(17.9) 8(25) 7(17.5) 24(41.4) 0.55 0.16
Left  ventricular EF % 55.9 ± 7.4 59.2 ± 5.7 52.2 ± 6.6 57.3 ± 6.9 0.01 0.11
Systolic BP (mmHg) 132.1 ± 26.5 129.6 ± 24.7 128.7 ± 33.1 127.7 ± 18.4 0.89 0.56
Diastolic BP (mmHg) 72.4 ± 18.5 71.3 ± 14.9 71.6 ± 14.6 75.1 ± 12.1 0.95 0.15
Paroxysms/year 3.4 ± 1.4 3.2 ± 1.2 – – NA NA
Medical treatment
Aspirin (%) 23(82.1) 20(62.5) 2(5) 25(43.1) 0.01 0.79
Warfarin (%) 5(17.9) 12(37.5) 38(95) – 0.01 NA
RAS  blocker (%) 13(46.4) 16(50) 25(62.5) 26(44.8) 0.36 0.27
Calcium channel blocker (%) 3(10.7) 12(37.5) 9(22.5) 10(17.2) 0.05 0.32
Beta  blocker (%) 20(71.4) 19(59.4) 26(65) 21(36.2) 0.65 0.01
Antiarrhythmic drugs (%) 1(3.5) 2(6.2) 2(5) – 0.90 NA
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AF, atrial ﬁbrillation; BP, blood pressure; RAS, renin–angiotensin system; NA, not a
* Comparison between atrial ﬁbrillation subgroups namely paroxysmal, persisten
** Comparison between the control and atrial ﬁbrillation groups.
s 6.67 ± 1.14 ng/mL; p = 0.003 and 3.01 ± 1.54 mg/L vs
.16 ± 1.28 mg/L; p = 0.001, respectively). In subgroup analy-
is, resistin levels were signiﬁcantly higher only in patients
ith paroxysmal (7.59 ± 1.57 ng/mL; p = 0.032) and persistent AF
7.73 ± 1.60 ng/mL; p = 0.006) compared to controls (Fig. 1). Resistin
ig. 1. Distribution of resistin levels in controls and patient subgroups stratiﬁed on
he basis of the type of AF. Middle line: mean; thin lines: ±1 standard deviation. AF,
trial ﬁbrillation.
able 2
omparison of laboratory parameters in AF subgroups and control subjects.
Paroxysmal AF (n = 28) Persistent AF (n = 32) 
Hemoglobin (g/dL) 13.2 ± 2.3 13.8 ± 1.5 
WBC  count (103/L) 9.1 ± 3.5 8.1 ± 2.1 
Platelet (103/L) 246.1 ± 68.1 259.7 ± 71.7 
Fasting glucose (mg/dL) 100.1 ± 11.3 101.2 ± 9.2 
Creatinine (mg/dL) 0.98 ± 0.41 0.88 ± 0.15 
hs-CRP (mg/L) 2.80 ± 1.71 2.84 ± 1.49 
Resistin (ng/mL) 7.59 ± 1.57 7.73 ± 1.60 
F, atrial ﬁbrillation; WBC, white blood cell; hs-CRP, high-sensitivity C-reactive protein.
* Comparison between atrial ﬁbrillation subgroups namely paroxysmal, persistent, and
** Comparison between the control and atrial ﬁbrillation groups.ble.
 permanent atrial ﬁbrillation.
levels in permanent AF patients were signiﬁcantly lower than in
patients with paroxysmal/persistent AF patients (p = 0.05) and were
similar to the control group (p = 0.92). Whereas, only permanent
AF patients had signiﬁcantly higher levels of hs-CRP compared to
the control group (3.26 ± 1.46 mg/L vs 2.16 ± 1.28 mg/L; p = 0.002).
In patients with paroxysmal and persistent AF the CRP levels
(2.80 ± 1.71 mg/L and 2.84 ± 1.49 mg/L, respectively) were not
statistically higher than controls (Table 2).
Laboratory and clinical parameters were compared in parox-
ysmal/persistent AF patients grouped according to the rate of
AF recurrence. In patients with ≥4 episodes/year age, BMI,
fasting blood glucose, creatinine, resistin (1.76 ± 0.32 ng/mL
vs 1.39 ± 0.25 ng/mL, respectively; p = 0.35), and hs-CRP levels
(2.75 ± 1.71 mg/L vs 2.89 ± 1.48 mg/L, respectively; p = 0.73) were
not statistically different from patients with ≤3 episodes/year.
In the study population, resistin levels were correlated with
CRP (r = 0.16; p = 0.04), creatinine (r = 0.26; p = 0.01), and fasting
plasma glucose (r = 0.16; p = 0.04) levels. C-reactive protein lev-
els were also correlated with plasma creatinine levels (r = 0.18;
p = 0.02). Signiﬁcant correlation of resistin and CRP levels with
other parameters including rate of AF recurrence were not
established.
In multivariate regression analysis using model adjusted for age,
gender, BMI, hypertension, diabetes mellitus, and creatinine levels,
plasma resistin levels [odds ratio (OR): 1.30; 95% conﬁdence inter-
val (CI): 1.01–1.70; p = 0.04] and hs-CRP levels (OR: 1.44; 95% CI:
1.12–1.86; p = 0.004) were the only independent predictors of AF.
Permanent AF (n = 40) Control (n = 58) p* p**
13.1 ± 1.8 13.4 ± 1.6 0.21 0.77
7.8 ± 2.3 9.2 ± 3.8 0.14 0.08
233.9 ± 59.6 243.8 ± 71.8 0.26 0.88
98.5 ± 12.6 97.6 ± 16.7 0.61 0.32
0.89 ± 0.30 0.84 ± 0.31 0.36 0.15
3.26 ± 1.46 2.16 ± 1.28 0.39 0.001
6.86 ± 1.61 6.67 ± 1.14 0.05 0.003
 permanent atrial ﬁbrillation.
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iscussion
The main ﬁnding of this study is that resistin levels are increased
n AF patients compared to controls. In addition, resistin levels
re correlated with hs-CRP levels which may  indicate the role of
nﬂammation in AF.
Resistin is anadipocytokinine which is secreted from lipid cells
nd has been shown to be associated with obesity. The resistin lev-
ls are higher in obese individuals as compared to individuals of
ormal weight and this correlates with BMI  [11]. Studies done on
atients who have inﬂammation proved that a correlation existed
etween resistin and inﬂammation markers. On a cellular level,
esistin seems to activate proinﬂammatory cytokines to create a
otent proinﬂammatory effect [32].
Resistin’s potential role in the cardiovascular disease process
ave been shown in various trials. It is an important marker in stable
oronary artery disease, acute coronary syndromes, heart failure,
nd it is also associated with prognosis [13–25].
AF is associated with inﬂammation, diabetes, obesity, coro-
ary artery disease, and heart failure which are associated with
ncreased resistin levels, and other pro-inﬂammatory adipocy-
okines secreted from the adipose tissue that may  contribute to
F either directly or indirectly through risk factors or inﬂamma-
ion [31]. The inﬂammation triggers an electrical and structural
emodeling process in AF patients [4,5]. Frustaci et al. detected his-
ological changes indicating inﬂammation in the atrial tissue [33].
diponectin is another important adipocytokinine secreted from
ipid cells. In a study conducted with adiponectin, when compared
ith a control group, plasma adiponectin levels were found to be
inked to persistent AF but not paroxysmal AF. In this trial, increased
ollagen products were shown to increase in paroxysmal and per-
istent groups in relation to atrial remodeling and ﬁbrosis [34]. In
ur study, we included permanent AF patients as well. Being related
o obesity and inﬂammation, two factors that play an important
ole in AF pathogenesis, the marker resistin was found signiﬁcantly
igher in the patient group as compared to the control group. The
ame was true for paroxysmal and persistent subtypes, as well.
lthough the resistin levels were higher in permanent AF than in
ontrol group, it was not of statistical signiﬁcance. One may  con-
lude that the inﬂammatory marker secreted from adipose tissue,
esistin, and atrial inﬂammation bear importance in patients with-
ut AF during transition to paroxysmal and persistent AF. A growing
ody of evidence suggests a possible association between inﬂam-
ation and permanent atrial ﬁbrillation, but inﬂammatory reaction
ight be of low-grade that resistin secretion could not reach sta-
istical signiﬁcance in comparison to control patients. However,
RP levels in the permanent AF group were signiﬁcantly higher
han controls in our study. Some previous papers reported statis-
ically insigniﬁcant higher CRP levels in patients with permanent
one AF, and suggested a link between a low-grade inﬂammatory
eaction and long-lasting AF [10,35,36]. Nevertheless, CRP levels
ere found signiﬁcant in those with comorbidities and permanent
F [6,7]. We  thought that comorbidities in our permanent AF group
ggravated existing low-grade inﬂammation resulting in high CRP
evels but not resistin. The evidence of resistin levels in permanent
one AF and none-lone AF compared to controls is lacking. Large-
cale randomized trials are needed to precisely evaluate this issue.
f our results were conﬁrmed with large-scale studies, we assume
hat this issue may  help clinicians differentiate the type of AF in
symptomatic patients. The differentiation of AF by itself may  guide
linicians in choosing rhythm control or rate control strategy; if an
symptomatic AF patient has a high resistin level one may  suppose
hat it might be converted to sinus rhythm. In our study, CRP and
esistin proved to be independent risk factors for AF development
n the multivariate analysis and its increase in conjunction with
RP also supports its role in the pathophysiology of the disease.
[
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Two  trials have been conducted on resistin and AF recently. As
a substudy of the Framingham trial, the basal resistin levels were
measured in 2487 individuals who did not have AF. They were fol-
lowed up for 10 years for AF development. In this study, plasma
resistin and CRP levels were found to correlate with AF develop-
ment [31]. It was also determined that CRP and resistin levels were
signiﬁcantly correlated but when CRP was  added to resistin, its
effect decreased in multivariate analyses. Similar to this one, our
results also suggested that CRP and resistin levels were increased
parallelly and were related to AF in multivariate analyses. In Gungor
et al.’s study from Turkey [37], the post-operative plasma resistin
levels were found to be important in predicting post-operative AF
development in 40 coronary artery bypass graft patients. Inﬂam-
mation’s role in post-operative AF development may  explain the
increase in resistin levels in this group of patients.
Conclusion
As a result, we found that plasma resistin levels were higher
in AF patients when compared to the control group and that they
differed by the type of disease; patients with paroxysmal and per-
sistent form of AF have signiﬁcantly higher resistin levels while
it was insigniﬁcant in permanent AF patients compared to con-
trol group. Our study, like other studies in the literature, supports
resistin’s potential role in AF and cardiovascular disease processes.
More extensive studies are required to fully understand the rela-
tionship between adipocytokines and AF.
Limitations
We only measured resistin levels in our study, not adiponectin
or other adipocytokines. It is a cross-sectional study and the patient
number is not high. It is also conducted in a single center. As we
excluded more types of comorbidities that are often associated with
AF, our study cannot be generalized to all AF patients.
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